Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMedical weight loss injections are prescription-only medicines — currently tirzepatide (Mounjaro) and semaglutide (Wegovy) — licensed in the UK for adults with obesity or excess weight and a related health condition. They reduce appetite and slow gastric emptying by acting on gut-hormone receptors, and in clinical trials produced average weight reductions of 15–21% over roughly 68–72 weeks. These are not cosmetic or quick-fix treatments; they are serious medicines that require clinical assessment before a prescriber can issue a prescription.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the misconception our prescribers encounter most often, and it matters enough to address head-on. Medical weight loss injections are not appetite-suppressants tacked onto an existing diet plan. Tirzepatide (sold as Mounjaro) activates two gut-hormone receptors simultaneously: GIP and GLP-1. Semaglutide (Wegovy) activates the GLP-1 receptor alone. Both pathways reduce how hungry you feel between meals and slow the rate at which food leaves the stomach, which means people eat less without the constant mental effort of restriction. The biology being targeted is the same biology that makes sustained weight loss so difficult for most people without medical support. The NHS tirzepatide medicines page explains this mechanism clearly for anyone who wants the patient-level detail.
Trial results reflect that difference. In the SURMOUNT-1 study, participants using tirzepatide at the highest dose lost an average of around 20–21% of body weight over 72 weeks. Semaglutide produced around 15% average loss over 68 weeks in the STEP 1 trial. These figures are from people who also made changes to diet and activity, the injection is one part of the programme, not a replacement for it.
What the injections do not do is override individual biology entirely. Results vary. Some people respond more strongly than others, and a prescriber assesses this as treatment progresses rather than at the start.
Both medicines come as pre-filled, once-weekly injection pens. The injection itself is subcutaneous (into the layer of fat just beneath the skin, not into muscle) and the needle is short enough that most people find it far less daunting than they expected. Injection sites rotate between the abdomen, thigh and upper arm to avoid skin irritation building up in one spot. Our guide to injecting weight loss medication walks through the technique step by step if that is something you want to read before your consultation.
Storage is straightforward: keep the pen in the fridge door between uses (2–8°C), and the needle tip pointing upward once attached. There is a limited window during which the pen can be kept at room temperature if you are travelling, the exact timeframe is in the Patient Information Leaflet that comes with your pen, and that is the right reference to follow rather than any general online figure.
Tirzepatide treatment starts at 2.5 mg. The starter dose exists to let your system adjust rather than to produce weight loss, nausea is more common in the first weeks, and the gradual schedule reduces it. A prescriber increases the dose in steps, typically every four weeks, based on how you are tolerating treatment. The same titration principle applies to semaglutide. If you are based in Merseyside and would prefer face-to-face support, our page on medical weight loss injections in Liverpool covers what that involves locally. For a clear overview of the medicines currently available in the UK and what distinguishes them, the weight loss injection medication names page covers that ground.
UK licensing requires adults to have a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition, conditions such as type 2 diabetes, high blood pressure, obstructive sleep apnoea or raised cholesterol. BMI thresholds are 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, in line with NICE's appraisal of tirzepatide (TA1026).
Meeting those numbers is not itself enough. A prescriber looks at the whole picture: current medicines, relevant medical history, contraindications, and whether the medicine is appropriate for you specifically. Neither tirzepatide nor semaglutide is recommended during pregnancy, breastfeeding or if you are trying to conceive. They are not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma, MEN2, or a history of pancreatitis will need careful prescriber discussion before treatment could be considered.
If you are curious whether you might qualify, the consultation page is the starting point, our prescribers review each case individually and will tell you plainly what they find.
The most common side effects of medical weight loss injections are gastrointestinal: nausea, diarrhoea, constipation, indigestion, burping and, less often, vomiting. These are typically most noticeable in the early weeks or after a dose increase, and they usually ease as your body adapts. Fatigue and headache are also reported, particularly at the start.
A smaller number of people experience more significant effects. Acute pancreatitis is a known but infrequent risk: the MHRA issued a Drug Safety Update in January 2026 specifically highlighting it for GLP-1 medicines. The symptom to act on promptly is severe, persistent stomach pain that radiates towards the back, with or without vomiting, that warrants same-day medical attention rather than waiting to see if it passes. Gallbladder symptoms, signs of a serious allergic reaction, and significant dehydration from repeated vomiting or diarrhoea are other reasons to contact a healthcare professional quickly.
You can report any suspected side effect from a medical injection for weight loss directly to the MHRA via the Yellow Card scheme. It takes a few minutes and contributes to the ongoing safety monitoring that keeps these medicines as well-understood as possible. If you would rather read about injection technique and aftercare before starting, the team is reachable through the contact page.
If injections are not the right fit for you, it is worth knowing that the landscape of options has widened. The non-injection weight loss medication page covers alternatives that may be relevant depending on your circumstances. If cost is a consideration, you can also find out how to spread the payments for a weight loss medication injection using weight loss injections with Klarna, which some patients find makes starting treatment more manageable.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.